Psoriasis Clinical Trials in Philadelphia
View 35 new treatments for Psoriasis in Philadelphia, PA. Every day, Power helps hundreds of Psoriasis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Secukinumab for Nail Psoriasis
Research Clinic, Philadelphia + 1 more
This study will be an open label study of secukinumab for the treatment of nail psoriasis. Secukinumab is an FDA-approved treatment for psoriasis. We will examine time to response and different methods of defining nail disease response.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 3 - 6 Weeks
Alexis Ogdie-Beatty, MD
Principal Investigator
Deucravacitinib for Palmoplantar Pustulosis
Research Clinic, Philadelphia + 1 more
This trial tests a pill called deucravacitinib in adults with severe PPP who haven't responded to other treatments. The medication aims to reduce inflammation and calm the immune system, improving symptoms like redness and swelling. Deucravacitinib has shown efficacy in treating moderate to severe plaque psoriasis.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Bimekizumab for Psoriatic Arthritis
UCB Biopharma Clinic, Wyomissing + 1 more
This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
UCB Cares
Study Director
ESK-001 for Psoriasis
Alumis Clinic, Philadelphia + 1 more
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Wyomissing + 1 more
The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Waitlist
Phase 3
Est. 5 - 8 Weeks
AbbVie Inc.
Study Director
Risankizumab for Psoriatic Arthritis
AbbVie Clinic, Wyomissing + 1 more
The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in participants with moderately to severely active psoriatic arthritis (PsA).Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
ABBVIE INC.
Study Director
JNJ-77242113 for Plaque Psoriasis
Janssen Clinic, Philadelphia + 1 more
The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.Show More
Waitlist
Phase 3
Est. 3 - 12 Weeks
Janssen Research & Development, LLC Clinicaltrial
Study Director
Certolizumab Pegol for Plaque Psoriasis
UCB Biopharma Clinic, Philadelphia + 1 more
The purpose of the study is to demonstrate the efficacy and safety of certolizumab pegol in the treatment of moderate to severe chronic plaque psoriasis in study participants aged 6 to 11 and 12 to 17 years.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
UCB Cares
Study Director
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Exton + 2 more
The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director
JNJ-77242113 for Plaque Psoriasis
Janssen Clinic, Exton + 1 more
This trial is testing a new medication called JNJ-77242113 to see if it helps people with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches. The study aims to find out if this new treatment can improve symptoms for those who have not responded well to other treatments.Show More
Waitlist
Phase 3
Est. 4 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Page 1 of 3
Frequently Asked Questions
Explore related conditions